Reshma Ramlal, MD

Cancer Focus:
Leukemia, Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)

Bone Marrow Transplant and Cellular Immunotherapy Specialist

Expert in Allogeneic transplant for Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), and Transplantation in Older Adults

Dr. Reshma Ramlal is a hematologist-oncologist at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. She specializes in bone marrow transplantation and cellular immunotherapy, with a clinical and research focus on allogeneic transplantation for myeloid malignancies, including acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. She is particularly recognized for advancing safe and effective transplantation in the elderly population, offering individualized treatment plans that emphasize both survival and quality of life.

In her clinical practice, Dr. Ramlal provides expert care in allogeneic stem cell transplantation and the prevention, diagnosis, and treatment of transplant-related early and late complications. She is known for her evidence-based, compassionate approach and for guiding patients and families through every phase of the transplant journey—from pre-transplant evaluation through long-term survivorship.

Nationally, Dr. Reshma Ramlal has made significant contributions to advancing education, quality improvement, and patient outcomes in cancer care. She serves as Chair of the Committee on Education for the American Society for Transplantation and Cellular Therapy (ASTCT) and as Chair-Elect of the Item Writing Task Force for the American Society of Clinical Oncology (ASCO). Through these roles, she helps shape the next generation of standards in bone marrow and stem cell transplantation.

Her recognitions include Leukemia and Lymphoma Society Woman of the Year (Lexington, Kentucky Chapter, 2020), ASCO Educational Scholars Program (2025), and American College of Physicians Florida Chapter Outstanding Resident of the Year for Excellence in Internal Medicine (2012). She also completed the Harvard Medical School Executive Education Training in Artificial Intelligence in Health Care, underscoring her commitment to innovation and the future of precision medicine.

Dr. Ramlal earned her Medical Degree from The University of the West Indies, St. Augustine, graduating first in Medicine and Therapeutics with Honors. She completed her Internal Medicine Residency at the University of Florida College of Medicine in Jacksonville, her Hematology and Oncology Fellowship at Saint Louis University School of Medicine, and an advanced Stem Cell Transplantation and Cellular Therapy Fellowship at The University of Texas MD Anderson Cancer Center.

• Chen J, Ahmed T, Ahmed T, Iragavarapu C, Ramlal R, Arbune A. Multimodality Imaging Guided Diagnosis and Treatment Response Evaluation in a Patient with Lymphoma with Right Atrioventricular Involvement. Curr Probl Cardiol. 2022 Sep.47(9):101273. Pubmedid: 35661810.
• Burkeen CG, Pottinger D, Iragavarapu C, Ramlal R, Hildebrandt G. Myocarditis Concurrent with Sweet Syndrome: A Presentation of Acute Myeloid Leukemia. Case Rep Hematol. 2021.2021:6621007. Pubmedid: 34055428. Pmcid: PMC8133866.
• Qasrawi A, Ramlal R, Munker R, Hildebrandt GC. Prognostic impact of Philadelphia chromosome in mixed phenotype acute leukemia (MPAL): A cancer registry analysis on real-world outcome. Am J Hematol. 2020 Sep.95(9):1015-1021. Pubmedid: 32419244.
• Myint ZW, Shrestha R, Siddiqui S, Slone S, Huang B, Ramlal R, Monohan GP, Hildebrandt GC, Saeed H. Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: An analysis from Kentucky Cancer Registry. Hematol Oncol Stem Cell Ther. 2020 Mar.13(1):17-22. Pubmedid: 31629724.
• Qasrawi A, Gomes V, Chacko CA, Mansour A, Kesler M, Arora R, Wei S, Ramlal R, Munker R. Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database. Leuk Res. 2020 Feb.89:106301. Pubmedid: 31982153.
• Qasrawi A, Arora R, Ramlal R, Munker R, Hildebrandt GC. Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma. Am J Hematol. 2020 Apr.95(4):E89-E91. Pubmedid: 31919891.
• Siddiqui S, Ramlal R. "Myelodysplasia" from copper deficiency. Blood. 2019 Feb.133(8):883. Pubmedid: 30792227.
• Hickey E, Clemons B, Griffin S, Cox J, Sutphin S, Ramlal R, Benitez L. Multicenter evaluation of arsenic trioxide dosing in obese patients with low-intermediate risk acute promyelocytic leukemia. Leuk Lymphoma. 2019 Dec.60(14):3557-3560. Pubmedid: 31294640.
• Ramlal R, Hildebrandt GC. Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease. Biomedicines. 2017 May.5(2). Pubmedid: 28536366. Pmcid: PMC5489809.
• Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood. 2017 Jun.129(22):3031-3033. Pubmedid: 28351938. Pmcid: PMC6033074.
• Shah D, Shrestha R, Ramlal R, Hatton J, Saeed H. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Ann Oncol. 2017 Jun.28(6):1403. Pubmedid: 28368439.
• Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2017 Jul.31(7):1654-1657. Pubmedid: 28400618. Pmcid: PMC6192023.
• Woelich SK, Braun JT, Schoen MW, Ramlal R, Freter CE, Petruska PJ, Lionberger JM. Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia. Anticancer Res. 2017 Feb.37(2):713-717. Pubmedid: 28179321.
• Poddar N, Ramlal R, Ravulapati S, Devlin SM, Gadani S, Vidal CI, Cao D, Befeler AS, Lai J. Extrahepatic metastasis of hepatocellular carcinoma arising from a hepatic adenoma without concurrent intrahepatic recurrence. Curr Oncol. 2017 Aug.24(4):e333-e336. Pubmedid: 28874904. Pmcid: PMC5576473.